#New York #FDA #Pomerantz Law Firm #INOVIO Pharmaceuticals

Pomerantz Law Firm Investigates Inovio Pharmaceuticals

In a recent development that has caught the attention of investors and the financial community alike, Pomerantz LLP has announced an investigation into Inovio Pharmaceuticals, Inc. This scrutiny comes after significant events concerning the company’s stock and its recent interactions with the FDA surrounding their Biologics License Application (BLA) for INO-3107.

What Prompted the Investigation?

Pomerantz LLP, a leading law firm known for its expertise in securities class action lawsuits, is investigating whether Inovio and its high-ranking officials engaged in any unlawful business practices, including securities fraud. This investigation is particularly critical given the company's recent announcements and the subsequent impact on its stock performance.

On December 29, 2025, the U.S. Food and Drug Administration (FDA) made headlines by accepting Inovio’s BLA for INO-3107, which is aimed at treating recurrent respiratory papillomatosis. However, the complications arose when the FDA stated that Inovio failed to provide adequate information to qualify for accelerated approval, leading to a significant decline in the company's stock price. Following this announcement, Inovio’s stock plummeted by 24.45%, closing at $1.73 per share, a substantial fall that sparked concerns among investors and drew the attention of Pomerantz LLP.

The Firm’s Historical Context

Pomerantz LLP has a distinguished reputation for fighting against corporate misconduct, having been established over 85 years ago by the late Abraham L. Pomerantz. Known as the